Abstract: Systems and methods to identify new protein targets of a chemical compound or its derivatives were described. The methods can be used for detection of new binding partners as long as the chemical compound can covalently bind to the protein targets. Once protein targets are resolved, information related to new protein targets can then be used to couple with real-world patient data such as adverse events, efficacy data, and disease correlation data to deduce real-world evidence. Systems collectively with all this information can aide clinical development and use of pharmaceutical drug. Methods are provided for detection of covalently bound phenyl vinyl sulfone (PVS) or its derivatives, and afatinib or its derivatives. Furthermore, generation of antiserum recognizing carrier bound PVS or carrier bound afatinib is described. PRMT1 is described as a new target of PVS and RRM1, RRM2, and NFKB are described as new targets of afatinib.

Abstract: Systems and methods to identify new protein targets of a chemical compound or its derivatives were described. The methods can be used for detection of new binding partners as long as the chemical compound can covalently bind to the protein targets. Once protein targets are resolved, information related to new protein targets can then be used to couple with real-world patient data such as adverse events, efficacy data, and disease correlation data to deduce real-world evidence. Systems collectively with all this information can aide clinical development and use of pharmaceutical drug. Methods are provided for detection of covalently bound phenyl vinyl sulfone (PVS) or its derivatives, and afatinib or its derivatives. Furthermore, generation of antiserum recognizing carrier bound PVS or carrier bound afatinib is described. PRMT1 is described as a new target of PVS and RRM1, RRM2, and NFKB are described as new targets of afatinib.

Abstract: The present invention discloses a novel isolated antibody that specifically binds to an N-phenyl-acetamide group. Also disclosed are related compositions, kits, methods for detecting protein S-nitrosylation or oxidation vivo or in vitro, and drug screening methods.

Abstract: The present invention discloses a novel isolated antibody that specifically binds to an N-phenyl-acetamide group. Also disclosed are related compositions, kits, methods for detecting protein S-nitrosylation or oxidation vivo or in vitro, and drug screening methods.

Abstract: The present invention relates to a method of protein electrolysis, comprising: (a) providing a protein sample, which contains a salt selected from alkali metal salts or alkaline earth metal salts having a concentration of 20 mM or above; (b) electrolytically reducing said protein sample; (c) obtaining an electroreduced protein sample. The present invention also relates to a protein obtained by the above-mentioned protein electrolysis method, and a use of said method for protein modification.